Oxidant injury and antioxidant prevention: role of dietary antioxidants, minerals, and drugs in the management of coronary heart disease (Part II)

Ethnopharmacological Survey, Mineral and Chemical Content, In Vitro Antioxidant, and Antibacterial Activities of Aqueous and Organic Extracts of Chamaerops humilis L. var. argentea Andre Leaves

Introduction. The present study is carried out for the first time on Chamaerops humilis L. var. argentea Andre from the region of Taza using an ethnopharmacological survey, an experimental study of the mineralogical and chemical compositions, and evaluations of the antioxidant and antibacterial activities. Methods. After conducting the ethnopharmacological survey, a mineralogical and phytochemical study involving the preparation of aqueous and organic extracts was done. Essential oils were also extracted by hydrodistillation. Subsequently, qualitative and quantitative chemical analyses were performed. In vitro evaluation of antioxidant activities was performed by five tests (H2O2, DPPH, ABTS, FRAP, and RP) and antibacterial activities by the disc method and determination of MIC and MBC. A principal component analysis (PCA) was performed to visualize the different correlations. Results. The different parts of the plant are used for the treatment of digestive disorders, cardiovascular diseases, and diabetes. In addition, the leaves are rich in mineral compounds, catechic tannins, flavonoids, and sterols. However, they have some traces of essential oils. The quantitative analysis revealed that the ethanolic macerated had a higher content of total polyphenols ( $100.27\pm 1.95\text{mg}$ EAG/g E) and catechic tannins ( $52.11\pm 1.02\text{mg}$ EC/g E). This extract had a strong antioxidant capacity (H2O2 ( $37.34\pm 0.55\%$ ), DPPH ( $\text{I}{\text{C}}_{50}=31.18\pm 0.66\mu \text{g}/\text{ml}$ ), ABTS ( $108.28\pm 1.29\text{mg}$ E AA/g E), FRAP ( $148.85\pm 0.43\text{mg}$ E T/g E), and RP ( $10.86\pm 0.01\text{mg}$ E AA/g E). The same extract had a bactericidal effect against Staphylococcus aureus. Principal component analysis (PCA) showed that antioxidant activity was highly correlated with the chemical composition of C. humilis leaves; a high correlation was recorded between the total polyphenol content and ABTS ( $r=0.9779$ ), FRAP ( $r=0.9644$ ), DPPH ( $r=0.9418$ ), and PR ( $r=0.9271$ ) tests. In addition, cathectic tannins were highly correlated with the tests of DPPH ( $r=0.9753$ ) and ABTS ( $r=0.8843$ ). Flavonoids were similarly correlated with DPPH ( $r=0.8897$ ) and ABTS ( $r=0.7599$ ) tests. Conclusion. These results could justify the traditional use of the leaves of Chamaerops humilis in the region of Taza for the treatment of some diseases.

Antioxidant strategies in respiratory medicine

Pulmonary oxidant stress plays an important pathogenetic role in disease conditions including acute lung injury/adult respiratory distress syndrome (ALI/ARDS), hyperoxia, ischemia-reperfusion, sepsis, radiation injury, lung transplantation, COPD, and inflammation. Reactive oxygen species (ROS), released from activated macrophages and leukocytes or formed in the pulmonary epithelial and endothelial cells, damage the lungs and initiate cascades of pro-inflammatory reactions propagating pulmonary and systemic stress. Diverse molecules including small organic compounds (e.g. gluthatione, tocopherol (vitamin E), flavonoids) serve as natural antioxidants that reduce oxidized cellular components, decompose ROS and detoxify toxic oxidation products. Antioxidant enzymes can either facilitate these antioxidant reactions (e.g. peroxidases using glutathione as a reducing agent) or directly decompose ROS (e.g. superoxide dismutases [SOD] and catalase). Many antioxidant agents are being tested for treatment of pulmonary oxidant stress. The administration of small antioxidants via the oral, intratracheal and vascular routes for the treatment of short- and long-term oxidant stress showed rather modest protective effects in animal and human studies. Intratracheal and intravascular administration of antioxidant enzymes are being currently tested for the treatment of acute oxidant stress. For example, intratracheal administration of recombinant human SOD is protective in premature infants exposed to hyperoxia. However, animal and human studies show that more effective delivery of drugs to cells experiencing oxidant stress is needed to improve protection. Diverse delivery systems for antioxidants including liposomes, chemical modifications (e.g. attachment of masking pegylated [PEG]-groups) and coupling to affinity carriers (e.g. antibodies against cellular adhesion molecules) are being employed and currently tested, mostly in animal and, to a limited extent, in humans, for the treatment of oxidant stress. Further studies are needed, however, in order to develop and establish effective applications of pulmonary antioxidant interventions useful in clinical practice. Although beyond the scope of this review, antioxidant gene therapies may eventually provide a strategy for the management of subacute and chronic pulmonary oxidant stress.